About talquetamab
GPRC5D×CD3 bispecific antibody
Used for
- Treats adults with relapsed or refractory multiple myeloma after several prior treatments.
Usual adult dose
Given under the skin using step-up doses, then usually 0.4 mg/kg weekly or 0.8 mg/kg every two weeks.
Common side effects
- Cytokine release syndrome
- Taste changes and dry mouth
- Skin and nail problems
- Infections and low blood counts
Important warnings
- Can cause life-threatening cytokine release syndrome and neurologic toxicity; requires monitoring during treatment.
- Can cause serious infections and reduced blood-cell counts.
- May cause mouth, skin, or nail problems that need monitoring and supportive care.
- Treatment requires step-up dosing and specialist supervision.
Pregnancy
May harm an unborn baby; effective contraception is recommended during treatment and for three months afterward.
Breastfeeding
Avoid breastfeeding during treatment and for three months after the last dose.
Interactions
- May affect how the body processes some medicines; review other medicines with the oncology team.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.